Richard B. Lock

14.4k citations

277 papers · 11.9k · 1 hit paper · h-index 61

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
Oncology top 0.5%
- CAR-T cell therapy research
- Cancer-related Molecular Pathways

Papers in

Hematology 69
- Acute Myeloid Leukemia Research 44
- Chronic Myeloid Leukemia Treatments 27
Public Health, Environmental and Occupational Health 91
- Acute Lymphoblastic Leukemia research 88

Co-authors: Malcolm Anders Smith (88 shared papers)Peter John Houghton (79 shared papers)C. Patrick Reynolds (65 shared papers)Hernán Carol (73 shared papers)John M. Maris (65 shared papers)Stephen Thomas Keir (61 shared papers)Edward Anders Kolb (58 shared papers)Warren E. Ross (6 shared papers)
Journals: Pediatric Blood & Cancer (56 papers)Blood (29 papers)Leukemia (14 papers)Cancer Research (10 papers)Clinical Cancer Research (9 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Richard B. Lock

268 papers receiving 11.7k citations

Richard B. Lock's Hit Papers

align trajectories log scale

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia 2019 · 329 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2019 Cancer Cell

Peers

Countries citing papers authored by Richard B. Lock

Since Specialization

Citations

This map shows the geographic impact of Richard B. Lock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Lock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Lock more than expected).

Fields of papers citing papers by Richard B. Lock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Lock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Lock. The network helps show where Richard B. Lock may publish in the future.

Co-authors

The 25 scholars most cited alongside Richard B. Lock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard B. Lock Line = papers co-authored together Richard B. Lock links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 277 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells Cell stem cell ·Liqing Jin, Erwin M. Lee, Hayley S. Ramshaw, Samantha J. Busfield, Armando G. Peoppl, Lucy J. Wilkinson, Mark A. Guthridge, DANIEL W. THOMAS	2009	433
2	The pediatric preclinical testing program: Description of models and early testing results Pediatric Blood & Cancer ·Peter John Houghton, Christopher L. Morton, Chandra L. Tucker, Debbie Payne, Edward Favours, Claire Cole, Richard Greg Gorlick, Edward Anders Kolb	2006	410
3	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia Cancer Cell ·Andrei V. Krivtsov, Kathryn A Evans, Jayant Y. Gadrey, Benjamin K. Eschle, Charlie Hatton, Hannah J. Uckelmann, Kenneth N. Ross, Florian Perner Hit paper breakdown →	2019	329
4	Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells Cell Death and Differentiation ·Kathleen M. Murphy, Velvizhi Ranganathan, M L Farnsworth, Maria Kavallaris, Richard B. Lock	2000	317
5	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer Nature Medicine ·Marie Wong, Chelsea Mayoh, Loretta M. S. Lau, Dong-Anh Khuong-Quang, Mark Pinese, Amit Kumar, Paulette Barahona, Emilie E. Wilkie	2020	275
6	Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. PubMed ·Richard B. Lock, Warren E. Ross	1990	208
7	Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies Blood ·Natalia L. M. Liem, Rachael A. Papa, Christopher Milross, Michael Schmid, Mayamin Tajbakhsh, Seoyeon Choi, Carole Ramirez, Alison M. Rice	2004	207
8	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatric Blood & Cancer ·John M. Maris, Christopher L. Morton, Richard Greg Gorlick, Edward Anders Kolb, Richard B. Lock, Hernán Carol, Stephen Thomas Keir, C. Patrick Reynolds	2010	199
9	Premenstrual exacerbation of asthma. Thorax ·Clarence Joseph Gibbs, I I Coutts, Richard B. Lock, O C Finnegan, Richard White	1984	189
10	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia Blood ·Shannon L. Maude, Sibasish Dolai, Cristina Delgado-Martín, Tiffaney L. Vincent, Alissa K. Robbins, Arthavan Selvanathan, Theresa M. Ryan, Junior Hall	2015	188
11	Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. PubMed ·Richard B. Lock, Lolita Stribinskiene	1996	185
12	The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse Blood ·Richard B. Lock, Natalia L. M. Liem, Monica L. Farnsworth, Christopher Milross, Chengyuan Xue, Mayamin Tajbakhsh, Michelle Haber, Murray D. Norris	2002	164
13	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia Science Translational Medicine ·Gabriela Brumatti, Chunyan Ma, Najoua Lalaoui, Nhu-Y Nguyen, Mario Navarro, Maria C. Tanzer, Jennifer Richmond, Margherita Ghisi	2016	158
14	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program Pediatric Blood & Cancer ·Edward Anders Kolb, Richard Greg Gorlick, Peter John Houghton, Christopher L. Morton, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris	2008	150
15	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia Blood ·Seong Lin Khaw, Santi Suryani, Kathryn A Evans, Jennifer Richmond, Alissa K. Robbins, Raushan T. Kurmasheva, Catherine A. Billups, Stephen W. Erickson	2016	147
16	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter John Houghton, Christopher L. Morton, Edward Anders Kolb, Richard Greg Gorlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris	2007	138
17	Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Blood ·Min H. Kang, Yun Hee Kang, Barbara Szymanska, Urszula Wilczynska-Kalak, Michael Allen Sheard, Theresa M. Harned, Richard B. Lock, C. Patrick Reynolds	2007	132
18	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design Cell Reports ·Jo Lynne Rokita, Komal S. Rathi, Maria Cardenas, Kristen A. Upton, Joy C. Jayaseelan, Katherine L. Cross, Jacob Pfeil, Laura E. Egolf	2019	123
19	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors Cell Reports ·Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight, Rachael Ralli, Sangkyu Kim, Kellie-Marie Banks, Eva Vidacs, Clémence Virely	2013	120
20	Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. PubMed ·R S Gupta, Rajan Gupta, Barry Eng, Richard B. Lock, Warren E. Ross, Robert Hertzberg, Mary Jo Caranfa, Richard K. Johnson	1988	116

About Richard B. Lock

Richard B. Lock is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Oncology, Molecular Biology and Cancer Research, having authored 277 papers that have together received 11.9k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (88 papers), Acute Myeloid Leukemia Research (44 papers), Neuroblastoma Research and Treatments (29 papers), Cell death mechanisms and regulation (27 papers), Chronic Myeloid Leukemia Treatments (27 papers), Cancer therapeutics and mechanisms (26 papers), Cancer-related Molecular Pathways (19 papers) and CAR-T cell therapy research (17 papers). The work is most often cited by research in Hematology (2.2k citations), Oncology (3.2k citations), Cancer Research (1.4k citations), Molecular Biology (6.0k citations) and Neurology (1.2k citations). Richard B. Lock has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Malcolm Anders Smith, Peter John Houghton, C. Patrick Reynolds, Hernán Carol, John M. Maris, Stephen Thomas Keir, Edward Anders Kolb, Warren E. Ross, Richard Greg Gorlick and Christopher L. Morton. Their work appears in journals such as Pediatric Blood & Cancer, Blood, Leukemia, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Richard B. Lock

Impact in

Papers in i

In The Last Decade

Richard B. Lock

Richard B. Lock's Hit Papers

Peers

Countries citing papers authored by Richard B. Lock

Fields of papers citing papers by Richard B. Lock

All Works

About Richard B. Lock

Explore authors with similar magnitude of impact

Papers in